The Effects of Dexmedetomidine on cTnI and GP-BB in Patients Undergoing OPCABG
NCT ID: NCT03163693
Last Updated: 2017-05-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
40 participants
INTERVENTIONAL
2016-02-29
2017-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
To Evaluate if Dexmedetomidine Infusion Provides Renal Protection in Patients Undergoing Coronary Artery Bypass Graft
NCT05375188
Comparison of Dexmedetomidine and Remifentanil Infusion During CABG
NCT01572454
Comparison Between Lidocaine, Dexmedetomidine, and Their Combined Infusion in Subjects Undergoing Coronary Artery Bypass Graft
NCT01688648
Intraoperative Dexmedetomidine and Coronary Artery Bypass Graft Surgery
NCT06378827
Combined Use of Dexmedetomidine and Hydrocortisone to Prevent New Onset AF After CABG Surgery
NCT05674253
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group dexmedetomidine
20 eligible patients are received 0.5ug/kg dexmedetomidine intravenously 15 minutes before surgery
dexmedetomidine
receive dexmedetomidine 0.5 μg/kg
Group control
20 eligible patients are received equal volumes normal saline intravenously 15 minutes before surgery
normal saline
receive equal volume of normal saline
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
dexmedetomidine
receive dexmedetomidine 0.5 μg/kg
normal saline
receive equal volume of normal saline
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* ASA physical status III-IV
* Aged 40-70 years
* NYHA physical status II-III
Exclusion Criteria
* Atrioventricular block
* Echocardiography suggested:LVEF \<40%, LVED\>65mm
* Allergic to the drugs
40 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
General Hospital of Ningxia Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zhu Di
Role: PRINCIPAL_INVESTIGATOR
General Hospital of Ningxia Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
General Hospital of Ningxia Medical University
Yinchuan, Ningxia, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2015-NW-028
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.